2026 NPPES data Ophthalmic Plastic and Reconstructive Surgery Physician NPI 1811986060 M.D., PHD
Verify on CMS →

JOHN MANDEVILLE, M.D., PHD

Ophthalmic Plastic and Reconstructive Surgery Physician in EAST WEYMOUTH, Massachusetts. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
2K
Medicare Part D claims · 731 beneficiaries · Ophthalmic Plastic and Reconstructive Surgery Physician avg: 624
Generic prescribing
93%
generic claims · 7% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$16.26
1 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

JOHN MANDEVILLE, M.D., PHD filed 1,816 Medicare Part D claims in 2023 as a Ophthalmic Plastic and Reconstructive Surgery Physician in EAST WEYMOUTH, Massachusetts, prescribing 93% generic.

2K
Part D claims, 2023
93%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

JOHN MANDEVILLE, M.D., PHD's Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023 — across all CMS prescribers nationally

1,816 Top 17% higher than 83% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). Below this entry. 200–400: 182,923 prescribers (13%). Below this entry. 400–600: 90,619 prescribers (7%). Below this entry. 600–800: 56,224 prescribers (4%). Below this entry. 800–1,000: 40,919 prescribers (3%). Below this entry. 1,000–1,200: 31,827 prescribers (2%). Below this entry. 1,200–1,400: 26,224 prescribers (2%). Below this entry. 1,400–1,600: 21,710 prescribers (2%). Below this entry. 1,600–1,800: 19,072 prescribers (1%). Below this entry. 1,800–2,000: 16,451 prescribers (1%). This entry sits in this band. 2,000–2,200: 213,991 prescribers (16%). Above this entry. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

Board certification likely (heuristic — not verified)

JOHN MANDEVILLE, M.D., PHD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about JOHN MANDEVILLE, M.D., PHD?

Quality data not reported

NPI registry status

Active

Issued 10/20/2005

NPI 1811986060

Primary specialty

Ophthalmic Plastic and Reconstructive Surgery Physician

Rare

291 US NPIs in this specialty

Medicare Part D claims

1,816 191% vs specialty avg

2023 prescription claims

Specialty avg: 624

Specialty distribution in Massachusetts

How Ophthalmic Plastic and Reconstructive Surgery Physician compares to other specialties among Massachusetts providers

Massachusetts providers

Ophthalmic Plastic and Reconstructive Surgery Physician share within Massachusetts

1. Ophthalmic Plastic and Reconstructive Surgery Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Ophthalmic Plastic and Reconstructive Surgery Physician share within Massachusetts

Specialty board-certification context

Estimated specialty board-certified rate — Ophthalmic Plastic and Reconstructive Surgery Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Ophthalmic Plastic and Reconstructive Surgery Physician ABMS/AOA estimate

Est. board-certified rate (Ophthalmic Plastic and Reconstructive Surgery Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Ophthalmic Plastic and Reconstructive Surgery Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

JOHN MANDEVILLE, M.D., PHD appears in the CMS NPPES registry as a Ophthalmic Plastic and Reconstructive Surgery Physician provider holding M.D., PHD credentials at 97 LIBBEY INDUSTRIAL PKWY STE 100, EAST WEYMOUTH, MA, 02189, with a listed phone of (781) 331-3300. NPI 1811986060 was issued on 10/20/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what MANDEVILLE most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 1,816 prescription claims written by this provider, covering 731 Medicare beneficiaries and totaling roughly $21K in drug spend, split 7% brand-name and 93% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Ophthalmic Plastic and Reconstructive Surgery Physician is a narrow specialty nationwide, with 291 enrolled providers across 46 states and an average of 624 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

97 LIBBEY INDUSTRIAL PKWY STE 100
EAST WEYMOUTH, MA 02189

Provider Details

NPI 1811986060
Specialty Ophthalmic Plastic and Reconstructive Surgery Physician
Credentials M.D., PHD
Gender Male
NPI Issued 10/20/2005

Hospital and facility affiliations

Facilities where JOHN MANDEVILLE, M.D., PHD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

OPHTHALMIC CONSULTANTS OF BOSTON INC
BOSTON, MA

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for JOHN MANDEVILLE, M.D., PHD. Source: openpaymentsdata.cms.gov.

Total received

$16

Largest payer

Amgen Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Massachusetts BORIM 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~38K Massachusetts medical licensees in 2023 — they are NOT specific to JOHN MANDEVILLE, M.D., PHD. To verify JOHN MANDEVILLE, M.D., PHD's current license status, search the BORIM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

80
Total board actions, Massachusetts 2023
Across 78 cases
2.11
Actions per 1,000 licensees
Massachusetts statewide rate
probation
Most common action type
29 cases

BORIM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Massachusetts disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Generic-heavy

JOHN MANDEVILLE, M.D., PHD — brand share 7.0%
Specialty average (est.)

7% brand-name claims vs 93% generic, on 1,816 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

1,816
Total Claims
$21K
Total Drug Cost
731
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
1,862
Total Day Supply
18,506
Brand vs Generic
7% brand / 93% generic
Brand Drug Cost
$6K
Generic Drug Cost
$15K
Antibiotic Claims
433

Patient Demographics

Average Patient Age
76.0 years
Avg HCC Risk Score
1.07
Gender Split
67% female / 33% male
Age Distribution
<65: 31, 65-74: 291, 75-84: 296, 85+: 113

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What JOHN MANDEVILLE, M.D., PHD prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Erythromycin
Erythromycin Base
802
Cephalexin
315
Neomycin-Polymyxin-Dexameth
Neomycin/Polymyxin B/Dexametha
237
Alprazolam
158
Bacitracin-Polymyxin
Bacitracin/Polymyxin B Sulfate
76
Azithromycin
59
Doxycycline Monohydrate
46
Ofloxacin
28
Polymyxin B Sul-Trimethoprim
Polymyxin B Sulf/Trimethoprim
23

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Ophthalmic Plastic and Reconstructive Surgery Physician Overview

How JOHN MANDEVILLE, M.D., PHD fits within the Ophthalmic Plastic and Reconstructive Surgery Physician landscape nationally.

291
Ophthalmic Plastic and Reconstructive Surgery Physician Providers in US
46
States with Ophthalmic Plastic and Reconstructive Surgery Physician
624
Avg Claims per Provider

JOHN MANDEVILLE, M.D., PHD's 1,816 claims are above the specialty average of 624.

Nearby Ophthalmic Plastic and Reconstructive Surgery Physician Providers in Massachusetts

Other clinicians with the same primary specialty enrolled in Massachusetts, drawn from the same CMS NPPES roster as MANDEVILLE.

Compare Ophthalmic Plastic and Reconstructive Surgery Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is JOHN MANDEVILLE, M.D., PHD's specialty?
JOHN MANDEVILLE, M.D., PHD specializes in Ophthalmic Plastic and Reconstructive Surgery Physician and practices in EAST WEYMOUTH, Massachusetts. Credentials: M.D., PHD.
How much does JOHN MANDEVILLE, M.D., PHD prescribe under Medicare Part D?
In 2023, JOHN MANDEVILLE, M.D., PHD wrote 1,816 Medicare Part D claims totaling $21K in drug costs for 731 beneficiaries.
Where is JOHN MANDEVILLE, M.D., PHD located?
JOHN MANDEVILLE, M.D., PHD is located at 97 LIBBEY INDUSTRIAL PKWY STE 100, EAST WEYMOUTH, MA, 02189. Phone: (781) 331-3300.
What is JOHN MANDEVILLE, M.D., PHD's NPI number?
JOHN MANDEVILLE, M.D., PHD's National Provider Identifier (NPI) is 1811986060, issued on 10/20/2005.
Does JOHN MANDEVILLE, M.D., PHD prescribe more brand-name or generic drugs?
JOHN MANDEVILLE, M.D., PHD's prescribing is 7% brand-name and 93% generic drugs by claim count, with $6K in brand drug costs.
How many Ophthalmic Plastic and Reconstructive Surgery Physician providers are there in the US?
There are 291 Ophthalmic Plastic and Reconstructive Surgery Physician providers across 46 states in the US. The average Ophthalmic Plastic and Reconstructive Surgery Physician provider writes 624 Medicare Part D claims per year.
What drugs does JOHN MANDEVILLE, M.D., PHD prescribe most often?
Based on 2023 Medicare Part D data, JOHN MANDEVILLE, M.D., PHD's most frequently prescribed drugs include Erythromycin, Cephalexin, Neomycin-Polymyxin-Dexameth. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does JOHN MANDEVILLE, M.D., PHD accept Medicare?
JOHN MANDEVILLE, M.D., PHD appears in CMS Medicare data with 1,816 Part D claims and 731 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify JOHN MANDEVILLE, M.D., PHD's credentials?
JOHN MANDEVILLE, M.D., PHD's NPI is 1811986060 with credentials M.D., PHD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology